# Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

> **NCT01890772** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Timothy Morgan, MD**

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Telaprevir
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin
- **DIETARY_SUPPLEMENT:** Vitamin D

## Key facts

- **NCT ID:** NCT01890772
- **Lead sponsor:** Timothy Morgan, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-08
- **Primary completion:** 2015-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890772, "Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01890772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*